Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Esther Drill

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
Hepatology (Baltimore, Md.)|March 25, 2021
Genetic Determinants of Outcome in Intrahepatic CholangiocarcinomaThomas Boerner, Esther Drill, Linda M Pak, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung CancerSemanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, et al.
Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Cell Reports|April 5, 2018
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasJoshua D Campbell, Christina Yau, Reanne Bowlby, et al.
Cancer Discovery|October 17, 2018
Integrative Molecular Characterization of Malignant Pleural MesotheliomaJulija Hmeljak, Francisco Sanchez-Vega, Katherine A Hoadley, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Blood|October 15, 2021
A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomasAlison J Moskowitz, Paola Ghione, Eric Jacobsen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 11, 2024
Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin LymphomaPallawi Torka, Tatyana Feldman, Kerry J Savage, et al.
Hepatology (Baltimore, Md.)|March 25, 2021
Genetic Determinants of Outcome in Intrahepatic CholangiocarcinomaThomas Boerner, Esther Drill, Linda M Pak, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 27, 2022
Germline Pathogenic Variants Impact Clinicopathology of Advanced Lung CancerSemanti Mukherjee, Chaitanya Bandlamudi, Matthew D Hellmann, et al.
Nature Medicine|June 17, 2024
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trialSteven M Horwitz, Ajit J Nirmal, Jahan Rahman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Cell Reports|April 5, 2018
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous CarcinomasJoshua D Campbell, Christina Yau, Reanne Bowlby, et al.
Cancer Discovery|October 17, 2018
Integrative Molecular Characterization of Malignant Pleural MesotheliomaJulija Hmeljak, Francisco Sanchez-Vega, Katherine A Hoadley, et al.
Pageof 5